Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: Evidence from a meta-analysis of randomised trials

EuroIntervention

Volumn 7, Issue 8, 2011, Pages 985-994

  Navarese, Eliano Pio ^a   Kubica, Jacek ^a   Castriota, Fausto ^b   Gibson, C Michael ^c   De Luca, Giuseppe ^d   Buffon, Antonino ^e   Bolognese, Leonardo ^f   Margheri, Massimo ^g   Andreotti, Felicita ^e   Di Mario, Carlo ^h   De Servi, Stefano ⁱ  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b GVM Care Research   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f IRCCS POLICLINICO SAN DONATO   (Italy)

^g Azienda Ospedaliera   (Italy)

^h ROYAL BROMPTON HOSPITAL   (United Kingdom)

ⁱ Civic Hospital   (Italy)

Author keywords

Biodegradable stent; Drug eluting stent; Late thrombosis; Meta analysis; Randomised controlled trials

Indexed keywords

PACLITAXEL; POLYMER; RAPAMYCIN;

BIODEGRADABLE IMPLANT; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; CORONARY STENT; DEVICE SAFETY; DRUG ELUTING STENT; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STENT THROMBOSIS; SURVIVAL; SYSTEMATIC REVIEW;

ABSORBABLE IMPLANTS; DRUG-ELUTING STENTS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOSIS;

EID: 84855381389     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV7I8A155     Document Type: Review

References (27)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-23. (Pubitemid 37186209)
2. Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein PS, Cohen SA,Wang H, Cutlip DE, Moses JW. Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) trial. J Am Coll Cardiol. 2009;53:1488-97.
3. Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schomig A, Kastrati A. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv. 2009;2:291-9.
4. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation. 2005;112:270-8. (Pubitemid 40982311)
5. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109: 701-5. (Pubitemid 38222887)
6. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Available at: www.cochrane.org/resources/handbook/ [updated February 2010].
7. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:2700.
8. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51. (Pubitemid 46685903)
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta- analyses. BMJ. 2003;327:557-60.
10. Fleiss JL. Analysis of data from multiclinic trials. Control Clin Trials. 1986;7:267-75. (Pubitemid 17204882)
11. Egger M, Smith GD. Bias in location and selection of studies. BMJ. 1998;31:61-6.
12. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455- 63.
13. Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA 3rd, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB Jr, Schofer J, Buchbinder M, Wijns W; COSTAR II Investigators Group. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol. 2008;51:1543-52. (Pubitemid 351512313)
14. Mehilli J, Byrne RA, Wieczorek A, Iijima R, Schulz S, Bruskina O, Pache J, Wessely R, Schömig A, Kastrati A; Intracoronary Stenting and Angiographic Restenosis Investigators. Test Efficacy of Rapamycin-eluting Stents with Different Polymer Coating Strategies (ISAR-TEST-3). Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J. 2008;29:1975-82.
15. Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, Schulz S, Pache J, Fusaro M, Seyfarth M, Schömig A, Mehilli J; Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Investigators. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J. 2009;30:2441-9.
16. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, Di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jüni P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372:1163-73.
17. Chevalier B, Serruys PW, Silber S, Garcia E, Suryapranata H, Hauptmann K, Wijns W, Schuler G, Fath-Ordoubadi F, Worthley S, Thuesen L, Meredith I, Bressers M, Nagai H, Paunovic D. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus®, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention. 2007;2:426-34.
18. Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H, Koolen J, Hauptmann KE, Wijns W, Morice MC, Carrie D, van Es GA, Nagai H, Detiege D, Paunovic D, Serruys PW; NOBORI 1 Clinical Investigators. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial-Phase 2. Circ Cardiovasc Interv. 2009;2:188-95.
19. Muramatsu T, Iwabuchi M, Saito S, Hayashi Y, Ikari Y, Fujii K, Nanto S, Inoue N, Kimura T, Namiki A, Hirayama H, Doi O, Kashida M, Yajima J, Mitsudo K. A randomized comparison of Nobori biolimus A9 eluting stent with Cypher sirolimus eluting stent for coronary revascularization in Japanese population. J Am Coll Cardiol. 2010; 55:A192.E1800.
20. Ormiston JA, Abizaid A, Spertus J, Fajadet J, Mauri L, Schofer J, Verheye S, Dens J, Thuesen L, Dubois C, Hoffmann R, Wijns W, Fitzgerald PJ, Popma JJ, Macours N, Cebrian A, Stoll HP, Rogers C, Spaulding C; NEVO ResElution-I Investigators. Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions. Circ Cardiovasc Interv. 2010;3:556-64.
21. Byrne RA, Kufner S, Tiroch K, Massberg S, Laugwitz KL, Birkmeier A, Schulz S, Mehilli J; ISAR-TEST-3 Investigators. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart. 2009;95:1489-94.
22. Garg S, Serruys P. Biodegradable stents and non-biodegradable stents. Minerva Cardioangiol. 2009;57:537-65.
23. Dixon SR, Grines CL, O'Neill WW. The Year in Interventional Cardiology. J Am Coll Cardiol. 2009;53;2080-97.
24. Basalus MW, van Houwelingen KG, Ankone M, de Man FH, von Birgelen C. Scanning electron microscopic assessment of the biodegradable coating on expanded biolimus-eluting stents. EuroIntervention. 2009;4:505-10.
25. Asplund B, Sperens J, Mathisen T, Hilborn J. Effects of hydrolysis on a new biodegradable co-polymer. J Biomater Sci Polym Ed. 2006;6:615-30. (Pubitemid 44069697)
26. Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol. 1993;21:15-25. (Pubitemid 23031291)
27. Moreno R, Fernandez C, Sanchez-Recalde A, Galeote G, Calvo L, Alfonso F, Hernandez R, Sánchez-Aquino R, Angiolillo DJ, Villarreal S, Macaya C, Lopez-Sendon JL. Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. Eur Heart J. 2007;28:1583-91. (Pubitemid 47227108)